X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
MYLAN
Dec-14
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,7884,249-   
Low Rs1,9022,995-   
Sales per share (Unadj.) Rs860.81,454.8-  
Earnings per share (Unadj.) Rs57.1175.2-  
Cash flow per share (Unadj.) Rs122.0282.1-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.7723.2-  
Shares outstanding (eoy) m165.91378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x2.72.5 109.4%   
Avg P/E ratio x41.120.7 198.8%  
P/CF ratio (eoy) x19.212.8 149.7%  
Price / Book Value ratio x3.15.0 61.8%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,0341,370,471 28.4%   
No. of employees `00023.525.0 94.1%   
Total wages/salary Rs m32,1490-   
Avg. sales/employee Rs Th6,070.822,017.4 27.6%   
Avg. wages/employee Rs Th1,366.60-   
Avg. net profit/employee Rs Th402.52,652.4 15.2%   
INCOME DATA
Net Sales Rs m142,810550,436 25.9%  
Other income Rs m1,552-3,209 -48.4%   
Total revenues Rs m144,362547,228 26.4%   
Gross profit Rs m23,512136,896 17.2%  
Depreciation Rs m10,77240,427 26.6%   
Interest Rs m78823,743 3.3%   
Profit before tax Rs m13,50469,518 19.4%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3802,923 149.8%   
Profit after tax Rs m9,46866,309 14.3%  
Gross profit margin %16.524.9 66.2%  
Effective tax rate %32.44.2 771.3%   
Net profit margin %6.612.0 55.0%  
BALANCE SHEET DATA
Current assets Rs m104,984483,906 21.7%   
Current liabilities Rs m68,938378,318 18.2%   
Net working cap to sales %25.219.2 131.6%  
Current ratio x1.51.3 119.1%  
Inventory Days Days7478 95.2%  
Debtors Days Days104107 96.6%  
Net fixed assets Rs m104,385127,342 82.0%   
Share capital Rs m83019,465 4.3%   
"Free" reserves Rs m124,8860-   
Net worth Rs m125,716273,621 45.9%   
Long term debt Rs m25,089408,763 6.1%   
Total assets Rs m225,4431,102,120 20.5%  
Interest coverage x18.13.9 461.7%   
Debt to equity ratio x0.21.5 13.4%  
Sales to assets ratio x0.60.5 126.8%   
Return on assets %4.58.2 55.7%  
Return on equity %7.524.2 31.1%  
Return on capital %9.713.6 71.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m53,7070-   
CASH FLOW
From Operations Rs m18,03072,355 24.9%  
From Investments Rs m-14,883-57,061 26.1%  
From Financial Activity Rs m-4,440-19,066 23.3%  
Net Cashflow Rs m-1,236-3,772 32.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.3 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: GLENMARK PHARMA  CIPLA  DR. DATSONS LABS  FDC LTD.  LUPIN LTD  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

WOCKHARDT LTD. Surges by 7%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Nov 21, 2018 | Updated on Nov 21, 2018

WOCKHARDT LTD. share price has surged by 7% and its current market price is Rs 555. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT LTD. (up 7.0%) and DR. REDDYS LAB (up 7.2%). The top losers are TORRENT PHARMA and FORTIS HEALTHCARE (down 0.1%).

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS